Anaptysbio, Inc revenue
Anaptysbio, Inc's revenue was $235m in fiscal 2025, up 157.0% on the year before. Since fiscal 2015 ($17.6m) it has grown at a compound 29.6% a year. Over the last twelve months it was $238m.
Revenue history
| Fiscal year | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18 | 17 | 10 | 5 | 8 | 75 | 63 | 10 | 17 | 91 | 235 | 238 |
| Growth on the year before | — | −5.0% | −40.1% | −50.0% | +60.0% | +837.5% | −15.8% | −83.7% | +66.8% | +432.0% | +157.0% | — |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Royalty Management Company | $235M | 100.0% | ▲ 157.0% |
| Biopharma Company | $0 | 0.0% | — |
From Anaptysbio, Inc's 10-K filed March 3, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Anaptysbio, Inc | $238m | 92.9% | 163.9% |
| Rhythm Pharmaceuticals, Inc. | $240m | 53.5% | 76.3% |
| Ideaya Biosciences, Inc. | $234m | -70.1% | 94.0% |
| Puma Biotechnology, Inc. | $231m | -2.9% | 0.2% |
| Ligand Pharmaceuticals Inc | $254m | 1.0% | 18.2% |
| Akebia Therapeutics, Inc. | $219m | 7.5% | 2.9% |
Compare with peers
- Rhythm Pharmaceuticals, Inc. revenue
- Ideaya Biosciences, Inc. revenue
- Puma Biotechnology, Inc. revenue
- Ligand Pharmaceuticals Inc revenue
- Akebia Therapeutics, Inc. revenue
Head to head: ANAB vs RYTMANAB vs IDYAANAB vs PBYIANAB vs LGND
More: Biotechnology stocks compared, Health Care sector, rankings of US companies